Kernal Biologics Overview
- Founded
- 2016
- Status
- Private
- Employees
- 16
- Latest Deal Type
- Series A
- Latest Deal Amount
- $20.1M
- Investors
- 35
Kernal Biologics General Information
Description
Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company's platform decreases immunogenicity upon existing mRNA technologies and enables cell-specific therapeutic protein expression, thereby providing clinicians with more efficacious, tolerable, and affordable medicine for the global market.
Contact Information
Website
www.kernalbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 700 Main Street
- Cambridge, MA 02139
- United States
+1 (857) 000-0000
Kernal Biologics Timeline
Kernal Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A) | 25-Feb-2022 | $20.1M | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series 2) | 04-Feb-2021 | 0000 | 000.00 | Completed | Pre-Clinical Trials | |
| 4. Seed Round | 21-Oct-2020 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 3. Accelerator/Incubator | 26-Aug-2020 | 00000 | 00000 | Completed | Pre-Clinical Trials | |
| 2. Accelerator/Incubator | 18-Oct-2018 | $500K | $850K | Completed | Pre-Clinical Trials | |
| 1. Angel (individual) | 14-Aug-2018 | $850K | $850K | Completed | Pre-Clinical Trials |
Kernal Biologics Patents
Kernal Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019319911-A1 | Precisely engineered stealthy messenger rnas and other polynucleotides | Pending | 09-Aug-2018 | 000000000000 | |
| CA-3109222-A1 | Precisely engineered stealthy messenger rnas and other polynucleotides | Pending | 09-Aug-2018 | 000000000000 | |
| US-20210317179-A1 | Precisely engineered stealthy messenger rnas and other polynucleotides | Pending | 09-Aug-2018 | 0000000000 | |
| EP-3833360-A1 | Precisely engineered stealthy messenger rnas and other polynucleotides | Pending | 09-Aug-2018 | C07K14/43595 |
Kernal Biologics Executive Team (5)
Kernal Biologics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Burak Yilmaz | Kernal Biologics | Co-Founder, President & Board Member | 000 0000 |
| Yusuf Erkul MD | Kernal Biologics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
Kernal Biologics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialKernal Biologics Investors (35)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Expanding Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| DO Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Explorer Equity Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Gaingels | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Scale Asia Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |